Loading data for GERN — first visit, this takes a few seconds.
Geron Corporation
1.35 -0.02 (-1.46%)
1.31 +1.54%
- Market Cap
- $828.8M
- Volume
- 9.87M
- Dividend yield
- n/a
- Next earnings date
- May 6, 2026
Geron Corporation (GERN) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $57.48M | n/a | +17.22% |
| EPS | -$0.02 | -$0.01 | +33.33% |
Metrics
- Bid
- 1.35
- Market Cap
- 829M
- Revenue (ttm)
- 205M
- Net Income (ttm)
- -67.6M
- 0.60
- -0.11
- n/a
- 32.25
- P/B (ttm)
- 3.79
- P/S (ttm)
- 4.05
- Earnings Date
- May 6, 2026
- Ask
- 1.56
- Volume
- 9,867,666
- Avg. Volume (20D)
- 11,290,633
- Open
- 1.38
- Previous Close
- 1.37
- Day's Range
- 1.34 - 1.41
- 52-Week Range
- 1.04 - 2.01
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Geron Corporation
View profile →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 1996
Employees 258
Stock Exchange NasdaqGS
Ticker Symbol GERN
Website https://www.geron.com